Table 3.
Mesenchymal stem cell-based protein therapies
| Disease/injury | Study organism | Cells | Mode of delivery | Outcome | References |
|---|---|---|---|---|---|
| Anaemia | Mouse | Epo-gene modified MSCs | Subcutaneous implantation | Anaemia corrected | [9] |
| Stroke | Rat | BDNF-modified telomerized human MSCs | Intracerebral | BDNF production improved functional recovery with fewer number of cells undergoing apoptosis in ischaemic boundary zone | [185] |
| Glioma | Rat | Human IL-2-modified MSCs | Intratumoral | Inhibited tumour growth and prolonged survival of tumour-bearing rats | [186] |
| Lung metastasis | Mouse | NK4-transduced MSCs | Intravenous | Inhibited development of lung metastasis; prolonged survival by inhibiting tumour-associated angiogenesis and lymphangiogenesis and apoptosis of tumour cells | [187] |